A Tonsillar PolyICLC/AT-2 SIV Therapeutic Vaccine Maintains Low Viremia Following Antiretroviral Therapy Cessation

• Panagiotis Vagenas,

  Affiliation HIV/AIDS Program, Population Council, Center for Biomedical Research, New York, New York, United States of America

  ⨯
• Meropi Aravantinou,

  Affiliation HIV/AIDS Program, Population Council, Center for Biomedical Research, New York, New York, United States of America

  ⨯
• Vennansha G. Williams,

  Affiliation HIV/AIDS Program, Population Council, Center for Biomedical Research, New York, New York, United States of America

  ⨯
• Edith Jasny,

  Affiliation HIV/AIDS Program, Population Council, Center for Biomedical Research, New York, New York, United States of America

  ⨯
• Michael Piatak Jr.,

  Affiliation AIDS and Cancer Virus Program, SAIC-Frederick, Inc., National Cancer Institute, Frederick, Maryland, United States of America

  ⨯
• Jeffrey D. Lifson,

  Affiliation AIDS and Cancer Virus Program, SAIC-Frederick, Inc., National Cancer Institute, Frederick, Maryland, United States of America

  ⨯
• Andres M. Salazar,

  Affiliation Oncovir Inc., Washington, D. C., United States of America

  ⨯
• James L. Blanchard,

  Affiliation Tulane National Primate Research Center, Tulane University, Covington, Louisiana, United States of America

  ⨯
• Agegnehu Gettie,

  Affiliation Aaron Diamond AIDS Research Center, Rockefeller University, New York, New York, United States of America

  ⨯
• Melissa Robbiani

  * E-mail: mrobbiani@popcouncil.org

  Affiliation HIV/AIDS Program, Population Council, Center for Biomedical Research, New York, New York, United States of America

  ⨯